Can't disagree with your points, apples. I think there would be a lot of uncertainty around and feel many are thinking about some of the points you raise. P&G is already a big winner because of our technology and the shoddy negotiations that were from years ago, but unfortunately at that stage in the game, it's what was required to even get P&G involved. They were the big fish. Still are. But the more I look at our management team and the conversations we have, let's just say OBJ is becoming more in the driver's seat. New negotiated terms in our favour for moving forward as well as them coming to us for product advancements and ideas for the future. From what I remember too from my discussions with management, our choice legal team/s can now go toe to toe with theirs.
I would be delighted to know what management thinks to your questions about P&G wanting it in house as well as why there's no insto's lining up at OBJ headquarters to invest, especially if it's groundbreaking technology and the way of the future.
You've said "to have this technology sitting outside of the company given so many wonderful future applications wouldn't sit well with senior management. As I said, this is the major reason that Insto's are on the sidelines and don't buy the story."
Question: how do you know this is the major reason they're on the sidelines? And what "Insto's" are you specifically referring to?
Just curious
I guess we'll see how this year plays out. Being at the speculative end we are off many radars anyway, but it's something I'd like to see growth in. Bigger players getting involved. Another thing too is any significant purchase of shares in the company right now makes it difficult without making a scene due to the low supply.
- Forums
- ASX - By Stock
- WFL
- Olay hits the Super Bowl
Olay hits the Super Bowl, page-11
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online